Breast Cancer

Results demonstrate improved progression-free survival in the overall patient population and in a prespecified biomarker subgroup of tumors with alterations in specific genes, AstraZeneca says.

By 2019, lung cancer mortality rates decreased by 5.4% in males since 2015, while deaths from ovary cancer have also declined rapidly over the past 2 decades.

Completing a breast cancer-focused continuing education credit and encouraging screenings are 2 ways that pharmacists can get involved during the month of October.

Further, the survey showed that fewer than half of women would flag redness of the breast, thickening of the skin, or 1 breast feeling warmer and heavier than the other as possible symptoms.

Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.

New agents can offer a more tailored approach to therapy selection.

In a trial, sacituzumab govitecan-hziy demonstrated a 34% reduction in the risk of disease progression or death compared with physician’s choice chemotherapy.

Higher C-reactive protein levels have been linked to cognition problems among older breast cancer survivors.

The FDA approved the only companion diagnostic that is indicated to assess low levels of HER2 proteins in patients with metastatic breast cancer.

Oncology pharmacists participate significantly in conversations, research, and publications of that research.

October is Breast Cancer Awareness Month.

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers.

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

Data showed that Black women, regardless of education level or income, are more likely to reside in disadvantaged neighborhoods, which may contribute to racial disparities in breast cancer.

Black women are suggested to be diagnosed with stage 3 HR-positive breast cancer and receive longer neoadjuvant endocrine therapy more often than White women.

Prior authorizations have delayed time to treatment for patients and can directly impact clinical outcomes.

Ribociclib with endocrine therapy was found to increase the median overall survival of patients with HR+/HER2- advanced breast cancer with visceral metastases to nearly 5 years.

New TROPiCS-02 data for Gilead treatment demonstrates progression-free survival benefit, regardless of HER2 status.

Analysis shows that over 5 years, the percentage of women without relapse was 89% for those who had hormonal stimulation of the ovaries and 83% for those with ovarian tissue freezing.

DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.

Women are 70% more likely to survive stage 1 breast cancer than stage 4, and new research shows that earlier screening could catch breast cancer earlier, increasing their survival rate.

The drug also meets the key secondary endpoint of improved overall survival for treatment for individuals with HER2 positive unresectable and/or metastatic breast cancer.

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.

Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.

Although some physicians caution against menopausal hormone therapy, a new study finds that it does not lead to breast cancer recurrence or mortality.

New study shows that race does not influence outcomes from immunotherapy for aggressive triple-negative breast cancer.

The FDA approved a new drug that treats unresectable and metastatic HER2-low breast cancer, giving patients with this new subtype a treatment beyond chemotherapy.

Patients can better understand the most current recommendations for breast cancer screening with the new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis.